Way back in this thread now, I made a comment for the benefit of a poster who said her GP would not allow her to have HRT because of a family history of heart disease. I said that, ironically, not having HRT could be detrimental.
This was picked up by @margolovebutter and @JaneJeffer both disputing by comment. They have continued to post out of date and erroneous studies to 'support' their case, mainly US stats.
This is in the report from the Australasion Society. It is fully referenced at the end.
It is almost word for word what I posted, yet other posters felt they knew better than all these international menopause doctors.
Cardiovascular disease is the leading cause of morbidity and mortality in postmenopausal women [1]. Hormone replacement therapy (HRT) has been shown to reduce future risk of cardiovascular disease when taken within 10 years of the menopause. Avoiding HRT in menopausal women can actually be detrimental to their health. Some experts are now recommending that HRT should be considered as part of a general prevention strategy for women at the onset of the menopause
@JaneJeffer- the UK and Europe have different guidelines around the use of HRT compared to the US.
In the UK, doctors follow NICE and the BMS. The BMS states quite categorically that there are no time limits on use of HRT (compared to your quote from the Mayo Clinic.)
As they say here in their consensus statement.
thebms.org.uk/publications/consensus-statements/hormone-replacement-therapy/
Summary points
1 All women should have access to advice so that they can make informed decisions about diet and lifestyle and treatment options to optimise their menopause transition and postmenopausal health.
2 HRT dosage, regimen and duration should be individualised, with annual evaluation of advantages and disadvantages.
3 Transdermal estradiol is unlikely to increase the risk of venous thrombosis or stroke above that of non-users and is associated with lower risk compared with oral estradiol.
4 Limited evidence suggests that micronised progesterone and dydrogesterone may be associated with lower risk of breast cancer and venous thrombosis compared to other progestogens.
5 Arbitrary limits should not be placed on the duration of use of HRT; if symptoms persist, the benefits usually outweigh the risks.
6 HRT prescribed before the age of 60 or within 10 years of the menopause has a favourable benefit /risk profile and is likely to be associated with a reduction in coronary heart disease and cardiovascular mortality.
7 If HRT is used in women over 60 years of age, low doses should be started, preferably with a transdermal estradiol preparation.
8 Women with POI should be encouraged to use hormonal therapy at least until the average age of the menopause.
HRT or the combined contraceptive pill would be suitable.
9 However, HRT may confer a more favourable improvement in bone density and cardiovascular markers compared with the combined contraceptive pill.